<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659058</url>
  </required_header>
  <id_info>
    <org_study_id>37801</org_study_id>
    <nct_id>NCT03659058</nct_id>
  </id_info>
  <brief_title>Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR</brief_title>
  <acronym>fib-reversal</acronym>
  <official_title>Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After Achieving Sustained Virological Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      with the introduction of Direct-acting antiviral agents in the management of HCV, the scope
      of inclusion criteria had been widened to include patients with compensated cirrhosis and
      even in special situations patients with decompensated liver disease; a chance that was not
      offered by the limited and strict inclusion criteria needed for treatment by pegylated
      interferon-based regimen. this made the number of patients with progressive liver fibrosis of
      cirrhosis had been inv=creased even after achieving SVR. the debate about the impact of SVR
      on halting fibrosis progression had risen; some studies postulated that patients benefit from
      an SVR through reduction of mortality, morbidity, and improved quality of life ; however,
      some patients may maintain their level of fibrosis or even progress to cirrhosis despite
      achieving SVR and the risk for HCC remains even after virologic eradication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2016</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>200 patients will receive silymarin 420 mg + antioxidants + colchicine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in liver stiffness measurement by Fibroscan</measure>
    <time_frame>1 year</time_frame>
    <description>Liver stiffness assessment by Fibroscan every 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improved portal hypertension parameters</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of portal vein diameter, splenic vein diameter, portal vein congestive index by ultrasound and Doppler every 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improved splenic stiffness measurement</measure>
    <time_frame>1 year</time_frame>
    <description>assessment by ultrasound and fibroscan</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Fibrosis, Liver</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be treated by anti-fibrotic agents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be followed up without any intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>silymarin</intervention_name>
    <description>silymarin 140 three times daily</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>silymarin 140</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>Ursodeoxycholic Acid 500</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>ursofalk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antioxidants</intervention_name>
    <description>Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>antox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.6</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FOLLOW UP</intervention_name>
    <description>follow up by abdominal ultrasound and fibroscan every 6 month for 1 year</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
    <other_name>ultrasound and fibroscan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic HCV

          -  compensated liver disease (Child class A-B)

          -  sustained virological response

          -  liver stiffness by fibroscan &gt;12.5 kPa denotes cirrhosis

        Exclusion Criteria:

          -  decompensated liver disease

          -  chronic active HCV

          -  hepatocellular carcinoma

          -  other liver diseases as alcoholic liver disease, autoimmune liver disease,
             drug-induced liver disease

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>November 23, 2018</last_update_submitted>
  <last_update_submitted_qc>November 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Amr Shaaban Hanafy</investigator_full_name>
    <investigator_title>Assistant professor of medicine</investigator_title>
  </responsible_party>
  <keyword>fibrosis</keyword>
  <keyword>HCV</keyword>
  <keyword>Reversal</keyword>
  <keyword>sustained virological response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

